Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 17.0% | 18.3% | 18.9% | 14.4% | 16.4% | 15.7% | 15.7% | 13.6% | 14.2% | 12.9% | 14.8% | 9.5% | 8.8% | 10.3% | 16.5% | 10.6% | 14.4% | 38.6% | 10.9% | 16.1% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 27.6%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Novartis AG have been 23.2% over the past three years, and 21.5% over the past five years.
As of today, Novartis AG's Return on Equity (ROE) is 27.6%, which is higher than industry median of 18.5%. It indicates that Novartis AG's Return on Equity (ROE) is Good.